REFERENCES
- Lee S, Fung C, Liu PY, et al. Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa: risk fac-tors and outcome. Infect Control Hosp Epidemiol 1999; 20: 205–207.
- Lepper PM, Grusa E, Reichl H, Högel J, Trautmann M. Consumption of imipenem correlates with g-lactam resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46 (9): 2920–2925.
- Chatzinikolaou, I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160: 501–509.
- De Tese R. Nosocomial infection caused by multi-resis-tant Pseudomonas aeruginosa: epidemiological analysis at HC-FMUSP. Revista da Sociedade Brasileira de Medicina Tropical 1998; 31 (5): 503–504.
- Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother 2003; 51: 347–352.
- Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum 13-lac-tams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diag Microbiol Infect Dis 2002; 43 (3): 239–243.
- Jones RN, Varnam, DJ. Antimicrobial activity of broad-spectrum agents tested against gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Diag Microbiol Infect Dis 2002; 44 (4): 379–382.
- Rotimi VO, Al-Sweih NA, Feteih J. The prevalence and antibiotic susceptibility pattern of Gram-negative bacterial iso-lates in two ICUs in Saudi Arabia and Kuwait. Diag Microbiol Infect Dis 1998; 30 (1): 53–59.
- Wood AJJ. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445–1453.
- Collins CH, Lyne PM, Grange JM. Microbiological methods. 7th Ed. Butterworth-Heinemann Ltd. Britain. 1995; 284-286.
- Bauer AM, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standard simple disk method. Am J Clin Pathol 1966; 45: 493–496.
- National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibili-ty testing. Eleventh Informational Supplement. Document M100-S11, 2001; Vol. 21. No. 1. NCCLS, Wayne, PA.
- Hsueh PR, Chen ML, Sun CC, et al. Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999. Emerg Infect Dis 2002; 8 (1): 63–68.
- Aka J, Dosso M, Michel G. Antibiotic resistance of Pseudomonas aeruginosa: a fact and a problem at the University Hospital Center of Cocody (Abidjan). Med Trop 1987; 47 (1): 53–59.
- Gales AC, Sader HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diag Microbiol Infect Dis 2002; 44 (3): 301–311.
- Shargel L, Mutnick AH, Souney PF, Swanson LN, Block LH. Comprehensive pharmacy review. 3rd Ed. Mass Publishing Co. 1997; 713-714.
- Jones RN, Pfaller MA, Marshall SA, Hollis RJ, Wilke WW. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metallo-enzymes. Diag Microbiol Infect Dis 1997; 29 (3): 187–192.
- Laverdière M, Gallimore B, Restieri C, Poonia K, Chow AW. In vitro synergism of ceftriaxone combined with amino-glycosides against Pseudomonas aeruginosa. Diag Microbiol Infect Dis 1994; 19 (1): 39–46.
- Nitzan Y, Sharon R, Maayan M, Steuerman C. Pseudomonas aeruginosa isolates from different medical insti-tutions. Isr J Med Sci 1985; 2 (10): 798–803.